Auris Medical AG products

Development of Bentrio™ (AM-301) has been completed. The product has been introduced to the market, starting in selected countries of the European Union.

The OligoPhore™ / SemaPhore™ technology has been extensively and successfully tested with various siRNA and mRNA sequences in numerous disease models in mice. For the development of our first proprietary drug product, AM-401 (OligoPhore™ siRNA targeting KRAS), we have initiated a program of IND-enabling studies.

AM-125 for the treatment of vertigo is expected to complete its Phase 2 TRAVERS trial in Q2 2022 and to move into Phase 3 in Q4 2022. Keyzilen^® (AM-101) for the treatment of acute inner ear tinnitus and Sonsuvi^® (AM-111) for the treatment of acute inner ear hearing loss have both been evaluated in Phase 3 trials, but will require further clinical testing. 

Bentrio™ is a drug-free nasal spray for personal protection against airborne viruses and allergens. Upon application into the nose, Bentrio™ forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with cells; in addition, the composition serves to bind such particles and help with their discharge and to humidify the nasal mucosa. Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms.